Sales data for Tivicay (dolutegravir) in 2023 is not publicly available at this time. Tivicay is an integrase inhibitor used in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.
How is Tivicay's Market Performance Tracked?
The sales performance of Tivicay is typically reported by its manufacturer, ViiV Healthcare, through quarterly and annual financial reports. These reports provide insights into revenue generated by the drug. DrugPatentWatch.com tracks patent information and exclusivity periods, which can influence market dynamics and future sales [1].
What is the Patent and Exclusivity Status of Tivicay?
Information regarding the specific patent expiry dates and market exclusivity for Tivicay in 2023 would be detailed in ViiV Healthcare's filings and patent databases. DrugPatentWatch.com offers resources to track patent lifecycles for pharmaceuticals [1].
Who are Tivicay's Main Competitors?
Tivicay competes in the HIV treatment market with other antiretroviral medications. Its primary competitors include other integrase strand transfer inhibitors (INSTIs) and drugs from different classes of antiretrovirals. ViiV Healthcare also manufactures other HIV medications, such as Triumeq and Dovato, which may also influence Tivicay's market share.
When Might Generic Versions of Tivicay Become Available?
The availability of generic versions of Tivicay depends on the expiry of its patents and any associated market exclusivity granted by regulatory bodies. These dates can vary by region. DrugPatentWatch.com can provide detailed information on patent expirations and potential generic entry timelines [1].
What Clinical Data Supports Tivicay's Use?
Tivicay's efficacy and safety have been established through numerous clinical trials. Key studies, such as the SPRING-2 and FLAMINGO-2 trials, demonstrated its non-inferiority to other established antiretroviral regimens in virologically suppressed adult patients with HIV-1 [2]. It is often used in combination therapies, contributing to sustained viral suppression and improved immunological outcomes.
What Are Patient Concerns Regarding Tivicay?
Patient concerns regarding Tivicay, like any medication, may include potential side effects and the management of chronic HIV infection. Common side effects can include insomnia and headache. The long-term safety profile and potential drug interactions are also subjects of interest for patients and healthcare providers.
Sources:
[1] https://drugpatentwatch.com/
[2] Clinical data for Tivicay (dolutegravir). ViiV Healthcare. (Note: Specific study citations for SPRING-2 and FLAMINGO-2 would typically be found in the drug's prescribing information or scientific publications, which are not directly accessible for citation here but are the basis for this information).